J. Goldman & Co’s Akero Therapeutics AKRO Stock Holding History

J. Goldman & Co’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,600	Closed	-$646K	–	552
2025 Q3	$646K	Buy	+13,600	New	+$659K	0.02%	366
2023 Q4	–	Sell	-20,500	Closed	-$1.04M	–	330
2023 Q3	$1.04M	Buy	+20,500	New	+$955K	0.04%	236
2023 Q2	–	Sell	-6,800	Closed	-$260K	–	370
2023 Q1	$260K	Buy	+6,800	New	+$303K	0.01%	302

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

J. Goldman & Co's AKRO Position: Q3 2025 in Review

J. Goldman & Co sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 65,628 shares — an estimated $3.18M sold.

J. Goldman & Co first reported a position in AKRO in Q1 2025 and held it in 2 quarters. The position peaked at $3.5M in Q2 2025. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

J. Goldman & Co reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
J. Goldman & Co sold 65,628 Akero Therapeutics shares in Q3 2025, an estimated $3.18M.
J. Goldman & Co first reported a position in Akero Therapeutics in Q1 2025 and held it in 2 quarters.
J. Goldman & Co's Akero Therapeutics position peaked at $3.5M in Q2 2025.
265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.